Company: SXTPW
Filing Date: 2025-09-05
Form Type: 424B5
Source: 0001213900-25-085050
Chunk: 37

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-09-05
Form: 424B5
Chunk 37
---
 estimate that we will receive
net proceeds from this offering of approximately $1.2 million, assuming the sale of all of the securities being offered pursuant to this
prospectus, after deducting the estimated Agent’s commissions and estimated offering expenses payable by us. However, because there
is no minimum offering amount required as a condition to the closing of this offering, the actual offering amount, the Agent’s commissions
and net proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth on the cover page
of this prospectus.

We currently intend to use
the net proceeds from this offering for clinical trials, our commercial programs, working capital and general corporate purposes.

We will retain broad discretion in the allocation
of the net proceeds from this offering and could utilize the proceeds in ways that do not necessarily improve our results of operations
or enhance the value of our common stock.

Pending application of the
net proceeds as described above, we intend to invest the net proceeds of this offering in a money market or other interest-bearing account.
The amounts and timing of our actual expenditures will depend upon numerous factors, including our sales and marketing and commercialization efforts, demand for our products, our operating costs and the other factors described under “ Risk Factors” in this prospectus supplement, the accompanying prospectus and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as modified by any subsequent Quarterly Reports on Form 10-Q. Accordingly, our management will have flexibility in applying the net proceeds from this offering. An investor will not have the opportunity to evaluate the economic, financial or other information on which we base our decisions on how to use the proceeds.

<div align='center'>S-22

DIVIDEND POLICY</div>

We have never paid any cash
dividends on our common stock to date. We currently intend to retain all of our future earnings, if any, to fund the development and growth
of our business and do not anticipate paying any cash dividends for at least the next five years, if ever. Any future determination as
to the payment of cash dividends on our common stock will be at our board of directors’ discretion and will depend on our financial
condition, operating results, capital requirements and other factors that our board of directors considers to be relevant.

<div align='center'>S-23

DILUTION</div>

If you invest in our common stock in this offering,
you will experience dilution to the extent of the